United Therapeutics (UTHR) Share-based Compensation (2009 - 2026)

United Therapeutics has disclosed Share-based Compensation across 18 years of filings, most recently posting $19.0 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 49.74% year-over-year to $19.0 million; the TTM figure through Jun 2026 stood at $155.4 million (up 12.36% YoY), while the FY2025 annual figure was $147.7 million, up 2.57% from the prior year.
• Share-based Compensation came in at $19.0 million for Q2 2026 at United Therapeutics, down from $58.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $65.5 million in Q2 2022 to a low of -$21.1 million in Q1 2022.
• Average Share-based Compensation over 5 years is $30.3 million, with a median of $31.8 million recorded in 2025.
• Year-over-year, Share-based Compensation sank 152.62% in 2022 and jumped 475.0% in 2023.
• Over 5 years, Share-based Compensation stood at $64.8 million in 2022, then sank by 74.38% to $16.6 million in 2023, then jumped by 62.65% to $27.0 million in 2024, then soared by 44.44% to $39.0 million in 2025, then plunged by 51.28% to $19.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $19.0 million in Q2 2026, $58.3 million in Q1 2026, and $39.0 million in Q4 2025.